

## **Hyperaldosteronism: how to discriminate among different disease forms?**

**Valentina Crudo, Silvia Monticone, Jacopo Burrello, Fabrizio Buffolo, Martina Tetti, Franco Veglio, Paolo Mulatero.**

### Affiliations

Division of Internal Medicine and Hypertension, Department of Medical Sciences, University of Torino, 10126 Torino, Italy

**Short title:** subtype diagnosis of primary aldosteronism

**Key words:** primary aldosteronism, aldosterone producing adenoma, adrenal vein sampling, secondary hypertension

**Corresponding author:** Paolo Mulatero, Division of Internal Medicine and Hypertension, Department of Medical Sciences, University of Torino, Via Genova 3, 10126, Torino, Italy.

e-mail: [paolo.mulatero@unito.it](mailto:paolo.mulatero@unito.it)

fax:-39-011-6336931; ph:-39-011-6336959

**Authors disclosure/conflict of interest:** the authors have nothing to disclose

**Source of Funding:** None

**Word count:** abstract: 112; manuscript: 2221 (excluded references and tables); number of tables: 2.

1 **Abstract**

2 Primary aldosteronism (PA), characterized by the inappropriate and excessive  
3 adrenal secretion of aldosterone, is the most common cause of secondary  
4 hypertension; PA has been shown to increase cardio- and cerebro-vascular risks  
5 in comparison with essential hypertension. PA is a multi-faceted disease, which  
6 comprises unilateral forms, benefitting from surgical treatment, and bilateral  
7 forms, which are best managed medically; PA is more frequently sporadic but in  
8 some cases displays a familial transmission pattern. For these reasons, it is  
9 important to diagnose PA early on and correctly distinguish and manage its  
10 different forms.

11 In this review, we analyze the different forms of PA, with attention on the  
12 diagnostic pathway and the genetics of the disease.

13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

1 **Introduction**

2 Primary aldosteronism (PA) is defined as a syndrome, characterized by an  
3 inappropriate secretion of aldosterone, independent of the renin-angiotensin  
4 system and of sodium homeostasis. PA prevalence increases with blood pressure  
5 severity reaching up to 20% in patients with resistant hypertension [1,2]. Recent  
6 studies have also uncovered wider effects of aldosterone that go beyond BP, and  
7 affect a number of different target organs, in particular determining higher cardio-  
8 and cerebro-vascular risks in PA patients as compared to essential hypertensives  
9 with a similar risk profile [3,4].

10 Therefore, early detection of PA, is fundamental to best manage short and long-  
11 term complications of this condition.

12 The two most common forms of PA are the aldosterone-producing adenoma  
13 (APA), which accounts for 30-35% of all cases, and the bilateral adrenal  
14 hyperplasia (BAH), the most common PA subtype accounting for 65-70% of PA  
15 patients [5]. The therapeutic approaches are different depending from the  
16 subtypes, surgical for unilateral PA forms and medical treatment with  
17 mineralocorticoid receptors (MR) antagonists for BAH [5]. It should be noted that  
18 a relevant proportion of patients with unilateral PA, previously considered affected  
19 by APA, display a multinodular unilateral adrenal hyperplasia with one or more  
20 nodules expressing CYP11B2 with immunohistochemistry evaluation [6,7].

21 These two forms of PA, both sporadic, together comprise the vast majority of all  
22 PA cases; less common, but nonetheless important in the diagnostic pathway, are  
23 the four familial forms. Recognition of these is important not only in the treatment  
24 of patient, but also in the screening of first-grade family members.

1 In this manuscript we will review the subtype diagnosis of sporadic and familial  
2 PA.

3

#### 4 **Diagnosis**

5 Diagnosis of PA is made by a screening test using the aldosterone to renin (or  
6 plasma renin activity ratio) [5]. Population with increased risk of PA that should  
7 be screened and the relationships and characteristics of different aldosterone and  
8 renin assay are described elsewhere [8-10]. Confirmation of the suspicion of PA  
9 is made by one of four confirmatory/exclusion tests: the intravenous saline  
10 loading test, the oral saline loading test, the fludrocortisone-suppression test and  
11 the captopril challenge test. Characteristics and performance of the different  
12 confirmatory tests are discussed elsewhere [5,11].

13

#### 14 **Imaging techniques and steroid measurements**

15 Once PA is confirmed, patients should undergo contrast-enhanced computed  
16 tomography (CT) scanning evaluation of the adrenal glands [5,12] as a first exam.  
17 CT findings can vary, from bilateral hyperplasia, to unilateral hyperplasia, to  
18 unilateral or bilateral micro and macro-nodules (diameter < 1 cm or > 1 cm).  
19 Lesions bigger than 4 cm are suspicious for the rare but deadly adrenal carcinoma  
20 [5]. CT displays several limitations: even using fine-cuts, CT may fail at identifying  
21 micro-APAs; moreover, it does not provide information on the functional role of  
22 the nodules, which can be especially crucial when bilateral lesions are observed  
23 [13].

1 Other imaging techniques are available: the Endocrine Society approves magnetic  
2 resonance as an alternative to contrast CT, though it admittedly provides a lower  
3 quality of space resolution, and lower specificity [5].

4 Among functional imaging,  $^{131}\text{I}$ -6 $\beta$ -iodomethyl-19-norcholesterol scintiscan has  
5 been abandoned; a more recent technique is the  $^{11}\text{C}$ -metomidate positron  
6 emission tomography (PET)-CT scan, that could be considered an alternative to  
7 AVS when this is unsuccessful, but that display a lower sensitivity and specificity  
8 that makes it not suitable to substitute AVS routinely [14]. One of the limits of  
9 metomidate is its low selectivity for CYP11B1 over CYP11B2. For this reason, a  
10 Japanese group has tested a new, more CYP11B2-specific tracer,  $^{18}\text{F}$ -CDP2230.  
11 However, this new technique needs to be tested in a prospective trial in  
12 comparison with AVS [15].

13 An additional instrument in the diagnosis of APA versus BAH has been suggested  
14 with the measurement of the so-called "hybrid" steroids 18-oxocortisol (18oxoF)  
15 and 18-hydroxycortisol (18OHF), that are produced in large amount in a  
16 consistent proportion of APA compared to BAH and incidentalomas [16,17].  
17 Recently, through a more complete steroid profiling using liquid chromatography  
18 - tandem mass spectrometry (LC-MS/MS) to simultaneously measure 7 different  
19 adrenal steroids, it was possible to distinguish APA from BAH in a consistent  
20 proportion of cases and to identify those APA with a specific somatic genetic  
21 alteration [18,19]. If this results will be confirmed in large prospective studies,  
22 steroid profiling by LC-MS/MS promise to be a preliminary test in order to identify  
23 PA patients with high probability of unilateral PA, thus reducing significantly the  
24 requirement for AVS procedures.

25

## 1 **Adrenal venous sampling**

2 Adrenal venous sampling, or AVS, is widely recognized as the gold standard  
3 technique in the distinction of unilateral from bilateral PA [5,12]. In a review of  
4 950 cases, imaging technique (either CT scanning or magnetic resonance)  
5 resulted in a wrong diagnosis in around 38% of cases compared to AVS [20]. CT  
6 scanning can suggest inappropriate adrenalectomy in patients with BAH and  
7 unilateral nodule, or miss the opportunity of cure by adrenalectomy in cases of  
8 unilateral PA and bilateral nodules (with only one having secretory activity) or  
9 normal appearing adrenals and undetected micro-APA [5,20]. The main pitfall of  
10 CT scanning is the lack of a proper identification of secretory activity of detected  
11 nodules; different parameters have been suggested, such as densitometry and  
12 contrast wash-out, but neither has been proven to provide definite answers in the  
13 distinction between secreting lesions and incidentalomas [5,21]. Therefore, when  
14 adrenalectomy is not contraindicated because of comorbidities, AVS should  
15 always be suggested as the only reliable technique for PA subtype diagnosis  
16 [5,22].

17 AVS is a complicated procedure, which not only requires an expert operator, but  
18 also an adequate preparation of the patient. In the 4-6 weeks leading to the  
19 procedure, it is suggested to treat hypertension with alpha-blockers and non-  
20 dyhydropyridine calcium channel blockers, as they display the least influence on  
21 the renin-angiotensin system; if these drugs are not sufficient to reach the desired  
22 blood pressure control, beta-blockers, ACE-inhibitors and angiotensin-receptors  
23 blockers can be considered, while drugs such as thiazides, loop diuretics,  
24 amiloride and mineralocorticoid receptors antagonists should be avoided since  
25 they affect AVS results and interpretation. Potassium levels should be kept within

1 normal range [22]. AVS can be performed both under basal or during cosyntropin  
2 infusion with similar results [23]. Pro and cons of the two procedures are  
3 described elsewhere [22].

4 During AVS a catheter is inserted percutaneously in a femoral vein and, through  
5 the use of contrast medium and fluoroscopy, the adrenal veins are singled out, and  
6 blood is gently drawn. Procedure techniques can be challenging, and an expert  
7 operator is required, as success rates can vary between 44% and 96%, according  
8 to the radiologist expertise [22,24,25].

9 Left adrenal vein cannulation is relatively easy, as the vein joins the inferior  
10 phrenic vein to create a common vessel that drains into the left renal vein. Right  
11 adrenal vein, on the other hand, creates a very sharp angle in its emergency  
12 directly into the inferior vena cava, which can be challenging to cannulate even for  
13 an expert radiologist [24,25]. To avoid potential errors determined by blood  
14 dilution during adrenal veins cannulations, aldosterone values are always  
15 “corrected” by cortisol since it is considered that this hormone is equally produced  
16 from the two adrenals in PA patients [5,22].

17 Cortisol measurement is also used to determine the correct cannulation of the  
18 adrenal veins. The two most important parameters measured during AVS are are  
19 the selectivity index (SI), which is the ratio between cortisol in the adrenal vein  
20 and cortisol in a peripheral vein (Table 1): this provides information about the  
21 adequacy of cannulation of the adrenal vein; and the lateralization index (LI)  
22 which determine the presence or not of a lateralization of aldosterone secretion.  
23 It is calculated as the ratio between cortisol-corrected aldosterone levels in one  
24 adrenal compare to the contralateral. A result of  $LI > 4$  is diagnostic for unilateral

1 PA (Table 1). A LI <3 is diagnostic for BAH. For LI between 3 and 4 other clinical  
2 parameters should be taken into account for final decision [5,21,26].

3 Another AVS parameter is the contralateral ration, that is the cortisol-corrected  
4 aldosterone ratio from the non-dominant adrenal vein in comparison with the  
5 peripheral vein (Table 1). A recent study has demonstrated that a contralateral  
6 suppression (i.e. a contralateral ratio <1) is not necessary to obtain cure or  
7 significant improvement of blood pressure levels after adrenalectomy [27].

8 AVS requires an experienced radiologist with an expertise in endovascular  
9 procedures, in order to minimize risks, most commonly the rupture of an adrenal  
10 vein during the procedure. The multi-centric study AVIS showed an inverse  
11 correlation between the experience of the radiologist and numbers of procedures  
12 done and the chance of complications [28]. The most serious complication of AVS  
13 is adrenal hemorrhage. A retrospective study analyzed 24 cases of adrenal  
14 hemorrhage in patients who underwent AVS in 6 different referral centers; of  
15 these, the majority involved the right adrenal, coherent with the difficulty in the  
16 right adrenal vein cannulation and were more frequent in older patients [29].  
17 Interestingly, among all the analyzed cases, only one needed long-term  
18 corticosteroid replacement therapy for adrenal insufficiency. All hemorrhages  
19 were minor, and controlled by medical therapy without the need for new surgery  
20 or blood transfusions [29].

21

## 22 **Genetics of PA**

23 Familial hyperaldosteronism (FH) account for up to 5-6% of all PA cases [30,31].

24 The first form of FH to be discovered is also named glucocorticoid-remediable  
25 aldosteronism (GRA, or FH-I), which is caused by the creation of a chimeric gene



1 from the fusion of the promoter region of the 11 $\beta$ -hydroxylase gene *CYP11B1* with  
2 the coding region of the aldosterone synthase gene, *CYP11B2* [32,33] (Table 2).  
3 This determines a regulation of aldosterone production under the very active  
4 *CYP11B1* (encoding 11 $\beta$ -hydroxylase) promoter, which is regulated by ACTH.  
5 Patients with GRA usually present hypertension in the first two decades of their  
6 lives, and an increased risk of cerebral hemorrhage; moreover they show high  
7 levels of hybrid steroids. Transmission is autosomal dominant, and the disease,  
8 once diagnosed, can be easily managed by administration of low doses of  
9 glucocorticoids, often associated with mineralocorticoid receptor blockers [34].  
10 FH-II is clinically undistinguishable from sporadic PA, and it is diagnosed by the  
11 familial pattern of the disease. Its genetics basis is still unknown, though a linkage  
12 to chromosome 7p22 has been suggested [35,36]. It is conceivable that more  
13 types of genetic alterations are responsible for this condition (Table 2).  
14 FH-III is has been recently described by Choi in 2011 [37]. This disease is  
15 characterized more frequently by very early onset of severe hypertension and  
16 hyperaldosteronism that require bilateral adrenalectomy in most cases. FH-III is  
17 determined by gain-of-function mutations of *KCNJ5* which *KCNJ5* encodes for the  
18 potassium inwardly-rectifying channel Kir 3.4 [34] (Table 2); the mutations cause  
19 the channel to lose its selectivity for potassium, allowing large quantities of  
20 sodium to enter the cell, thus causing a membrane depolarization and the  
21 activation of voltage-gated calcium channels, with calcium influx into the cell, and  
22 activation of the cascade that results in aldosterone overproduction [38]. It should  
23 be noted, that cases with more mild phenotypes have been described [34,39,40].  
24 Primary aldosteronism with seizures and neurological abnormalities (PASNA) is  
25 an extremely severe form of PA, caused by a germline mutation in *CACNA1D*, which

1 encodes a voltage-gated L-type calcium channel (Table 2); the mutations result in  
2 channel activation at less depolarized potentials, which in turn causes calcium  
3 influx and aldosterone production [41,42]. Only two cases have been diagnosed  
4 so far: both patients were diagnosed at a very young age from healthy parents; it  
5 is believed that their neurological impairment is so severe not to allow affected  
6 individuals to reproduce. Therefore, this condition is considered not-familial  
7 despite the genetic cause and is expected to be caused only by *de novo* mutations.  
8 The latest discovery in familial forms is FH-IV, described by Scholl et al. in 2015  
9 [43]: FH-IV is caused by a germline mutation in another voltage-gated calcium  
10 channel gene, CACNA1H, highly expressed in the *zona glomerulosa* (Table 2). All  
11 index cases had PA and severe hypertension diagnosed by the age of 10 years, but  
12 without neurological abnormalities. Inheritance of FH-IV is autosomal dominant,  
13 though with incomplete penetrance, as carrier parents did not show the same  
14 severe hypertension as the index cases [44] and also normotensive individuals  
15 with the mutation were observed.

16 Intriguingly, mutations in KCNJ5 and CACNA1D were also described as somatic  
17 mutations in sporadic APAs [42,45]. Other somatic mutations in genes  
18 responsible for aldosterone overproduction (*ATP1A1* and *ATP2B3*) or involved in  
19 cell proliferation (*CTNNB1*) have also been described but without evidence of  
20 similar alterations responsible for familial forms [46,47].

21 PA patients with APA carrying mutations display in some cases specific steroid  
22 profiles that may help clinicians in the decision making process of PA subtype  
23 diagnosis [18].

1 Genetic basis for sporadic BAH are less understood for the difficulty of studying  
2 adrenal glands from this patients. In some cases, KCNJ5 mutations have been  
3 described, not associated to FH-III [48].

4 Heterozygous germline mutations in the armadillo repeat containing 5 gene  
5 (ARMC5) have been shown in patients with hypercortisolism due to sporadic  
6 primary bilateral macronodular adrenal hyperplasia [49] and were also described  
7 in observed in African-American PA patients [50] but not in a cohort of Caucasian  
8 BAH patients [51].

9

## 10 **Conclusions**

11 PA is a multi-faceted disease, which can lead to severe cardio- and cerebro-  
12 vascular complications in affected patients. Different subtypes of disease benefit  
13 from different treatment options, and should therefore be carefully distinguished,  
14 in order to ensure the best management for the patients.

15

## 16 **Bibliography**

17 1. Mosso L, Carvajal C, González A, Barraza A, Avila F, Montero J, Huete A,

18 Gederlini A, Fardella C. Primary aldosteronism and hypertensive disease.

19 Hypertension 2003;42:161-5.

20 2. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P.

21 Hyperaldosteronism among black and white subjects with resistant

22 hypertension. Hypertension 2002;40:892-6.

23 3. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications

24 associated with primary aldosteronism: A controlled cross-sectional study.

25 Hypertension 2013;62:331-6.

1 4. Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, Crudo V,  
2 Burrello J, Milan A, Rabbia F, Veglio F. Long-term cardio- and cerebrovascular  
3 events in patients with primary aldosteronism. *J Clin Endocrinol Metab*  
4 2013;98:4826-33.

5 5. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M,  
6 Young WF, Montori VM. Case detection, diagnosis, and treatment of patients with  
7 primary aldosteronism: An endocrine society clinical practice guideline. *The*  
8 *Journal of Clinical Endocrinology & Metabolism* 2008;93:3266-81.

9 6. Dekkers T, ter Meer M, Lenders JW, Hermus AR, Schultze Kool L,  
10 Langenhuijsen JF, Nishimoto K, Ogishima T, Mukai K, Azizan EAB, Tops B,  
11 Deinum J, Küsters B. Adrenal nodularity and somatic mutations in primary  
12 aldosteronism: One node is the culprit? *J Clin Endocrinol Metab* 2014;99:E1341-  
13 51.

14 7. Monticone S, Castellano I, Versace K, Lucatello B, Veglio F, Gomez-Sanchez CE,  
15 Williams TA, Mulatero P. Immunohistochemical, genetic and clinical  
16 characterization of sporadic aldosterone-producing adenomas. *Mol Cell*  
17 *Endocrinol* 2015;411:146-54.

18 8. Monticone S, Viola A, Tizzani D, Crudo V, Burrello J, Galmozzi M, Veglio F,  
19 Mulatero P. Primary aldosteronism: Who should be screened? *Horm Metab Res*  
20 2012;44:163-9.

21 9. Burrello J, Monticone S, Buffolo F, Lucchiari M, Tetti M, Rabbia F, Mengozzi G,  
22 Williams TA, Veglio F, Mulatero P. Diagnostic accuracy of aldosterone and renin  
23 measurement by chemiluminescent immunoassay and radioimmunoassay in  
24 primary aldosteronism. *J Hypertens* 2016; Epub ahead of print.

- 1 10. Manolopoulou J, Fischer E, Dietz A, Diederich S, Holmes D, Junnila R,  
2 Grimminger P, Reincke M, Morganti A, Bidlingmaier M. Clinical validation for the  
3 aldosterone-to-renin ratio and aldosterone suppression testing using  
4 simultaneous fully automated chemiluminescence immunoassays. *J Hypertens*  
5 2015;33:2500-11.
- 6 11. Mulatero P, Monticone S, Bertello C, Mengozzi G, Tizzani D, Iannaccone A,  
7 Veglio F. Confirmatory tests in the diagnosis of primary aldosteronism. *Horm*  
8 *Metab Res* 2010;42:406-10.
- 9 12. Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, Tanabe A.  
10 Guidelines for the diagnosis and treatment of primary aldosteronism-the japan  
11 endocrine society 2009. *Endocrine Journal* 2011;58:711-21.
- 12 13. Patel SM, Lingam RK, Beaconsfield TI, Tran TL, Brown B. Role of radiology in  
13 the management of primary aldosteronism. *Radiographics* 2007;27:1145-57.
- 14 14. Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, Soloviev DV, Azizan EAB,  
15 Aigbirhio F, Gurnell M, Brown MJ. Evaluation of the sensitivity and specificity of  
16 (11)c-metomidate positron emission tomography (PET)-CT for lateralizing  
17 aldosterone secretion by conn's adenomas. *J Clin Endocrinol Metab*  
18 2012;97:100-9.
- 19 15. Abe T, Naruse M, Young WF, Kobashi N, Doi Y, Izawa A, Akama K, Okumura Y,  
20 Ikenaga M, Kimura H, Saji H, Mukai K, Matsumoto H. A novel cyp11b2-specific  
21 imaging agent for detection of unilateral subtypes of primary aldosteronism. *J*  
22 *Clin Endocrinol Metab* 2016;jc20153431.
- 23 16. Satoh F, Morimoto R, Ono Y, Iwakura Y, Omata K, Kudo M, Takase K, Seiji K,  
24 Sasamoto H, Honma S, Okuyama M, Yamashita K, Gomez-Sanchez CE, Rainey WE,  
25 Arai Y, Sasano H, Nakamura Y, Ito S. Measurement of peripheral plasma 18-

1 oxocortisol can discriminate unilateral adenoma from bilateral diseases in  
2 patients with primary aldosteronism. *Hypertension* 2015;65:1096-102.

3 17. Mulatero P, di Cella SM, Monticone S, Schiavone D, Manzo M, Mengozzi G,  
4 Rabbia F, Terzolo M, Gomez-Sanchez EP, Gomez-Sanchez CE, Veglio F. 18-  
5 hydroxycorticosterone, 18-hydroxycortisol, and 18-oxocortisol in the diagnosis  
6 of primary aldosteronism and its subtypes. *J Clin Endocrinol Metab* 2012;97:881-  
7 9.

8 18. Williams TA, Peitzsch M, Dietz AS, Dekkers T, Bidlingmaier M, Riester A,  
9 Treitl M, Rhayem Y, Beuschlein F, Lenders JWM, Deinum J, Eisenhofer G, Reincke  
10 M. Genotype-Specific steroid profiles associated with aldosterone-producing  
11 adenomas. *Hypertension* 2016;67:139-45.

12 19. Eisenhofer G, Dekkers T, Peitzsch M, Dietz AS, Bidlingmaier M, Treitl M,  
13 Williams TA, Bornstein SR, Haase M, Rump LC, Willenberg HS, Beuschlein F,  
14 Deinum J, Lenders JWM, Reincke M. Mass spectrometry--based adrenal and  
15 peripheral venous steroid profiling for subtyping primary aldosteronism. *Clinical*  
16 *Chemistry* 2016;clinchem-2015.

17 20. Kempers MJ, Lenders JW, van Outheusden L, van der Wilt GJ, Schultze Kool LJ,  
18 Hermus AdRMM, Deinum J. Systematic review: Diagnostic procedures to  
19 differentiate unilateral from bilateral adrenal abnormality in primary  
20 aldosteronism. *Ann Intern Med* 2009;151:329-37.

21 21. Blake MA, Cronin CG, Boland GW. Adrenal imaging. *AJR Am J Roentgenol*  
22 2010;194:1450-60.

23 22. Monticone S, Viola A, Rossato D, Veglio F, Reincke M, Gomez-Sanchez CE,  
24 Mulatero P. Adrenal vein sampling in primary aldosteronism: Towards a  
25 standardised protocol. *Lancet Diabetes Endocrinol* 2015;3:296-303.

1 23. Monticone S, Satoh F, Giacchetti G, Viola A, Morimoto R, Kudo M, Ikawura Y,  
2 Ono Y, Turchi F, Paci E, Veglio F, Boscaro M, Rainey WE, Ito S, Mulatero P. Effect  
3 of adrenocorticotrophic hormone stimulation during adrenal vein sampling in  
4 primary aldosteronism. *Hypertension* 2012;59:840-6.

5 24. Young WF. Primary aldosteronism: Renaissance of a syndrome. *Clin*  
6 *Endocrinol (Oxf)* 2007;66:607-18.

7 25. Daunt N. Adrenal vein sampling: How to make it quick, easy, and successful.  
8 *Radiographics* 2005;25 Suppl 1:S143-58.

9 26. Burrello J, Monticone S, Tetti M, Rossato D, Versace K, Castellano I, Williams  
10 TA, Veglio F, Mulatero P. Subtype diagnosis of primary aldosteronism: Approach  
11 to different clinical scenarios. *Horm Metab Res* 2015;47:959-66.

12 27. Monticone S, Satoh F, Viola A, Fischer E, Vonend O, Bernini G, Lucatello B,  
13 Quinkler M, Ronconi V, Morimoto R, Kudo M, Degenhart C, Gao X, Carrara D,  
14 Willenberg HS, Rossato D, Mengozzi G, Riester A, Paci E, Iwakura Y, Burrello J,  
15 Maccario M, Giacchetti G, Veglio F, Ito S, Reincke M, Mulatero P. Aldosterone  
16 suppression on contralateral adrenal during adrenal vein sampling does not  
17 predict blood pressure response after adrenalectomy. *J Clin Endocrinol Metab*  
18 2014;99:4158-66.

19 28. Rossi GP, Barisa M, Allolio B, Auchus RJ, Amar L, Cohen D, Degenhart C,  
20 Deinum J, Fischer E, Gordon R, Kickuth R, Kline G, Lacroix A, Magill S, Miotto D,  
21 Naruse M, Nishikawa T, Omura M, Pimenta E, Plouin PF, Quinkler M, Reincke M,  
22 Rossi E, Rump LC, Satoh F, Schultze Kool L, Seccia TM, Stowasser M, Tanabe A,  
23 Trerotola S, Vonend O, Widimsky J, Wu KD, Wu VC, Pessina AC. The adrenal vein  
24 sampling international study (AVIS) for identifying the major subtypes of  
25 primary aldosteronism. *J Clin Endocrinol Metab* 2012;97:1606-14.

1 29. Monticone S, Satoh F, Dietz AS, Goupil R, Lang K, Pizzolo F, Gordon RD,  
2 Morimoto R, Reincke M, Stowasser M, Mulatero P. Clinical management and  
3 outcomes of adrenal hemorrhage following adrenal vein sampling in primary  
4 aldosteronism. *Hypertension* 2016;67:146-52.

5 30. Stowasser M, Pimenta E, Gordon RD. Familial or genetic primary  
6 aldosteronism and gordon syndrome. *Endocrinol Metab Clin North Am*  
7 2011;40:343-68, viii.

8 31. Mulatero P, Tizzani D, Viola A, Bertello C, Monticone S, Mengozzi G, Schiavone  
9 D, Williams TA, Einaudi S, La Grotta A, Rabbia F, Veglio F. Prevalence and  
10 characteristics of familial hyperaldosteronism: The PATOGEN study (primary  
11 aldosteronism in torino-genetic forms). *Hypertension* 2011;58:797-803.

12 32. Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone  
13 secretion and low plasma renin activity relieved by dexamethasone. *Can Med*  
14 *Assoc J* 1966;95:1109-19.

15 33. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A  
16 chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes  
17 glucocorticoid-remediable aldosteronism and human hypertension. *Nature*  
18 1992;355:262-5.

19 34. Mulatero P, Monticone S, Rainey WE, Veglio F, Williams TA. Role of KCNJ5 in  
20 familial and sporadic primary aldosteronism. *Nat Rev Endocrinol* 2013;9:104-12.

21 35. Carss KJ, Stowasser M, Gordon RD, O'Shaughnessy KM. Further study of  
22 chromosome 7p22 to identify the molecular basis of familial hyperaldosteronism  
23 type II. *J Hum Hypertens* 2011;25:560-4.

24 36. Sukor N, Mulatero P, Gordon RD, So A, Duffy D, Bertello C, Kelemen L, Jeske Y  
25 Veglio F, Stowasser M. Further evidence for linkage of familial



1 hyperaldosteronism type II at chromosome 7p22 in italian as well as australian  
2 and south american families. *J Hypertens* 2008;26:1577-82.

3 37. Choi M, Scholl UI, Yue P, Björklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y,  
4 Patel A, Men CJ, Lolis E, Wisgerhof MV, Gellder DS, Mane S, Hellman P, Westin G,  
5 Åkerström G, Wang W, Carling T, Lifton RP. K<sup>+</sup> channel mutations in adrenal  
6 aldosterone-producing adenomas and hereditary hypertension. *Science*  
7 2011;331:768-72.

8 38. Williams TA, Monticone S, Crudo V, Warth R, Veglio F, Mulatero P. Visinin-like  
9 1 is upregulated in aldosterone-producing adenomas with KCNJ5 mutations and  
10 protects from calcium-induced apoptosis. *Hypertension* 2012;59:833-9.

11 39. Monticone S, Hattangady NG, Penton D, Isales CM, Edwards MA, Williams TA,  
12 Sterner C, Warth R, Mulatero P, Rainey WE. A novel Y152C KCNJ5 mutation  
13 responsible for familial hyperaldosteronism type III. *J Clin Endocrinol Metab*  
14 2013;98:E1861-5.

15 40. Monticone S, Bandulik S, Stindl J, Zilbermint M, Dedov I, Mulatero P, Allgaeuer  
16 M, Lee CCR, Stratakis CA, Williams TA. A case of severe hyperaldosteronism  
17 caused by a de novo mutation affecting a critical salt bridge kir3. 4 residue. *The*  
18 *Journal of Clinical Endocrinology & Metabolism* 2014;100:E114-8.

19 41. Scholl UI, Goh G, Stölting G, de Oliveira RC, Choi M, Overton JD, Fonseca AL,  
20 Korah R, Starker LF, Kunstman JW. Somatic and germline CACNA1D calcium  
21 channel mutations in aldosterone-producing adenomas and primary  
22 aldosteronism. *Nat Genet* 2013;45:1050-4.

23 42. Monticone S, Else T, Mulatero P, Williams TA, Rainey WE. Understanding  
24 primary aldosteronism: Impact of next generation sequencing and expression  
25 profiling. *Mol Cell Endocrinol* 2015;399:311-20.

1 43. Scholl UI, Stölting G, Nelson-Williams C, Vichot AA, Choi M, Loring E, Prasad  
2 ML, Goh G, Carling T, Juhlin CC, Quack I, Rump LC, Thiel A, Lande M, Frazier BG,  
3 Rasoulpour M, Bowlin DL, Sethna CB, Trachtman H, Fahlke C, Lifton RP.  
4 Recurrent gain of function mutation in calcium channel CACNA1H causes early-  
5 onset hypertension with primary aldosteronism. *Elife* 2015;4:e06315.

6 44. Korah HE, Scholl UI. An update on familial hyperaldosteronism. *Hormone and*  
7 *Metabolic Research* 2015;47:941-6.

8 45. Williams TA, Lenders JW, Burrello J, Beuschlein F, Reincke M. KCNJ5  
9 mutations: Sex, salt and selection. *Horm Metab Res* 2015;47:953-8.

10 46. Beuschlein F, Boulkroun S, Osswald A, Wieland T, Nielsen HN, Lichtenauer  
11 UD, Penton D, Schack VR, Amar L, Fischer E. Somatic mutations in ATP1A1 and  
12 ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension.  
13 *Nat Genet* 2013;45:440-4.

14 47. Åkerström T, Maharjan R, Sven Willenberg H, Cupisti K, Ip J, Moser A,  
15 Stålberg P, Robinson B, Iwen KA, Dralle H, Walz MK, Lehnert H, Sidhu S, Gomez-  
16 Sanchez CE, Hellman P, Björklund P. Activating mutations in CTNNB1 in  
17 aldosterone producing adenomas. *Sci Rep* 2016;6:19546.

18 48. Murthy M, Xu S, Massimo G, Wolley M, Gordon RD, Stowasser M,  
19 O'Shaughnessy KM. Role for germline mutations and a rare coding single  
20 nucleotide polymorphism within the KCNJ5 potassium channel in a large cohort  
21 of sporadic cases of primary aldosteronism. *Hypertension* 2014;63:783-9.

22 49. Assié G, Libé R, Espiard S, Rizk-Rabin M, Guimier A, Luscap W, Barreau O,  
23 Lefèvre L, Sibony M, Guignat L. ARMC5 mutations in macronodular adrenal  
24 hyperplasia with cushing's syndrome. *New England Journal of Medicine*  
25 2013;369:2105-14.

1 50. Zilbermint M, Xekouki P, Faucz FR, Berthon A, Gkourogianni A, Schernthaner-  
2 Reiter MH, Batsis M, Sinaii N, Quezado MM, Merino M, Hodes A, Abraham SB, Libé  
3 R, Assié G, Espiard S, Drougat L, Ragazzon B, Davis A, Gebreab SY, Neff R,  
4 Kebebew E, Bertherat J, Lodish MB, Stratakis CA. Primary aldosteronism and  
5 ARMC5 variants. *J Clin Endocrinol Metab* 2015;100:E900-9.

6 51. Mulatero P, Schiavi F, Williams TA, Monticone S, Barbon G, Opocher G, Fallo F.  
7 ARMC5 mutation analysis in patients with primary aldosteronism and bilateral  
8 adrenal lesions. *J Hum Hypertens* 2015;Epub ahead of print.

9

AVS Indices	Measurement	Clinical use	Cut-offs
Selectivity index (SI)	$\frac{\text{Cortisol}_{\text{adrenal vein}}}{\text{Cortisol}_{\text{peripheral vein}}}$	Adequacy of cannulation of the adrenal veins	SI > 3 = adrenal vein correctly cannulated
Lateralisation index (LI)	$\frac{\text{Aldosterone/Cortisol}_{\text{adrenal vein}}}{\text{Aldosterone/Cortisol}_{\text{contralateral adrenal vein}}}$	Differentiate unilateral from bilateral PA	LI > 4 = unilateral PA LI < 3 = bilateral PA
Contra-lateral ratio (CLR)	$\frac{\text{Aldosterone/Cortisol}_{\text{non-dominant adrenal vein}}}{\text{Aldosterone/Cortisol}_{\text{peripheral vein}}}$	Retro-inhibition of aldosterone secretion in the non-dominant adrenal gland	CLR < 1 and LI between 3 and 4 = unilateral PA

10

11 **Table 1. Calculation and clinical use of AVS indices**

	<b>FH-I</b>	<b>FH-II</b>	<b>FH-III</b>	<b>FH-IV</b>
<b>Gene</b>	Hybrid <i>CYP11B1/B2</i>	Unknown Linkage at 7p22	<i>KCNJ5</i>	<i>CACNA1H</i>
<b>Transmission</b>	AD	AD	AD	AD Incomplete penetrance
<b>Severity of hypertension</b>	Normotension to resistant	Normotension to resistant	Grade II to resistant hypertension	Normotension to resistant

<b>u-18oxoF u-18OHF</b>	Elevated	Not elevated	Mildly to extremely elevated	Normal
<b>Aldosterone response to dexamethasone</b>	Complete suppression	Partial reduction or no change	Paradoxical increase (in 1 family)	Suppression in 1 patient
<b>Adrenal CT scanning/Adrenal pathology</b>	Normal adrenal glands	BAH or APA	Bilateral hyperplasia or normal adrenals	Marked zona glomerulosa hyperplasia (in 1 patient)

1

2 **Table 2. Familial forms of primary aldosteronism.** FH-I = Familial  
3 Hyperaldosteronism type 1; FH-II = Familial Hyperaldosteronism type II; FH-III =  
4 Familial Hyperaldosteronism type III; FH-IV = Familial Hyperaldosteronism type  
5 IV; AD = autosomal dominant; CCBs = Calcium Channel Blockers; BAH = Bilateral  
6 Adrenal Hyperplasia; APA = Aldosterone Producing Adenoma

7